<p>根據最近向證券交易委員會（SEC）披露的信息，Acadian Asset Management LLC 在 2023 年第一季度將其在 Dr. Reddy's Laboratories Ltd（紐約證券交易所代碼：RDY - 免費報告）的股份增加了 1.6%。該基金在本季度額外收購了 23,582 股後，持有該公司 1,471,523 股股票。截至其最近的 SEC 文件，Acadian Asset Management LLC 持有的 Dr. Reddy's Laboratories 的股份約佔 0.18%，價值 1,940 萬美元。</p>
<ul>
<li>Teva Pharmaceuticals 股票：發掘這款仿製藥的價值</li>
</ul>
<p>其他幾家大型投資者最近也增加或減少了在 RDY 的持股。美國銀行（Bank of America Corp DE）在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 123.1%。美國銀行目前持有該公司 1,916,425 股股票，價值 3,026 萬美元，此前在上個季度額外收購了 1,057,584 股。Cetera Investment Advisers 在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 410.5%。Cetera Investment Advisers 目前持有該公司 20,720 股股票，價值 32.7 萬美元，此前在上個季度額外收購了 16,661 股。D. E. Shaw &amp; Co. Inc.在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 256.3%。D. E. Shaw &amp; Co. Inc.目前持有該公司 429,887 股股票，價值 678.8 萬美元，此前在上個季度額外收購了 309,239 股。德意志銀行（Deutsche Bank AG）在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 311.9%。德意志銀行目前持有該公司 171,602 股股票，價值 271 萬美元，此前在上個季度額外收購了 129,936 股。最後，Ethic Inc.在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 422.2%。Ethic Inc.目前持有該公司 23,073 股股票，價值 36.4 萬美元，此前在上個季度額外收購了 18,655 股。機構投資者持有該股票的 3.85%。</p>
<h2>Dr. Reddy's Laboratories 股票上漲 1.0%</h2>
<p>週五，NYSE RDY 的股票開盤價為 14.72 美元。該公司的債務與股本比率為 0.01，速動比率為 1.36，流動比率為 1.89。該公司的市值為 122.9 億美元，市盈率為 22.30，PEG 比率為 5.89，貝塔值為 0.32。該股票的 50 日移動平均價格為 14.34 美元，200 日移動平均價格為 14.09 美元。Dr. Reddy's Laboratories Ltd 的 52 周低點為 12.26 美元，52 周高點為 16.19 美元。</p>
<ul>
<li>2 只被忽視的股票，盈利卻下跌</li>
</ul>
<p>Dr. Reddy's Laboratories（NYSE:RDY - 獲取免費報告）最近一次發佈財報是在 7 月 23 日，報告顯示該季度每股收益為 0.20 美元，超出分析師一致預期的 0.18 美元，超出幅度為 0.02 美元。該季度的收入為 9.8882 億美元，而分析師預期為 882.7 億美元。Dr. Reddy's Laboratories 的股本回報率為 17.25%，淨利潤率為 16.99%。賣方分析師預計 Dr. Reddy's Laboratories Ltd 在當前年度的每股收益將為 0.8 美元。</p>
<h2>Dr. Reddy's Laboratories 增加股息</h2>
<p>該公司最近還宣佈了一項年度股息，於 8 月 6 日支付。7 月 10 日的股東獲得每股 0.0915 美元的股息。這比 Dr. Reddy's Laboratories 之前的年度股息 0.08 美元有所增加，代表 62.4% 的收益率。除息日期為 7 月 25 日。Dr. Reddy's Laboratories 的股息支付比率（DPR）目前為 10.61%。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>製藥公司 GSK：成為更健康的價值股</li>
</ul>
<p>多家研究機構最近對 RDY 發表了評論。滙豐銀行（HSBC）將 Dr. Reddy's Laboratories 的評級從 “持有” 上調至 “買入”，並在 6 月 5 日的研究報告中將其目標價從 14.44 美元上調至 16.90 美元。滙豐全球研究（Hsbc Global Res）在 6 月 5 日的研究報告中將 Dr. Reddy's Laboratories 的評級從 “持有” 上調至 “強烈買入”。最後，Zacks Research 在 8 月 15 日的研究報告中將 Dr. Reddy's Laboratories 的評級從 “強烈賣出” 上調至 “持有”。一位投資分析師給予該股票 “強烈買入” 評級，兩位給予 “買入” 評級，兩位給予 “持有” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 16.95 美元。</p>
<p><strong>閲讀我們對 RDY 的最新分析</strong></p>
<h2>關於 Dr. Reddy's Laboratories</h2>
<p>（免費報告）</p>
<p>Dr. Reddy's Laboratories Limited 及其子公司在全球範圍內作為一家綜合製藥公司運營。它通過全球仿製藥、製藥服務和活性成分（PSAI）及其他部門運營。該公司的全球仿製藥部門生產和銷售處方藥和非處方成品藥，這些藥物以品牌名稱或作為具有治療等效性的仿製成品劑型進行市場營銷，同時還參與生物製藥業務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Dr. Reddy's Laboratories</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>接近阻力位的高飛股票：3 只值得關注的股票</li>
<li>2 只上升的 CRM 平台股票，預計在 2025 年將大幅上漲</li>
<li>希捷科技在標準普爾 500 中領先：其 120% 漲幅背後的原因是什麼？</li>
<li>什麼是成長股及其投資方式</li>
<li>先鋒集團的 VUG ETF：您投資組合的終極成長 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJEWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJEWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在藥明康德嗎？</h2>
<p>在考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而藥明康德並不在名單上。</p>
<p>雖然藥明康德目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

如瑞迪博士

<p>Acadian Asset Management LLC 在第一季度將其在藥明康德（NYSE:RDY）的持股增加了 1.6%，額外購買了 23,582 股，總持股達到 1,471,523 股，價值 1,940 萬美元。包括美國銀行和德意志銀行在內的其他投資者也顯著增加了他們的持股。藥明康德的股票開盤價為 14.72 美元，市值為 122.9 億美元。該公司最近宣佈了股息增加，並獲得了多家研究機構的評級上調，普遍評級為 “適度買入”，平均目標價為 16.95 美元</p>

<p>Acadian Asset Management LLC boosted its stake in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 1.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,471,523 shares of the company's stock after acquiring an additional 23,582 shares during the quarter. Acadian Asset Management LLC owned about 0.18% of Dr. Reddy's Laboratories worth $19,404,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據最近向證券交易委員會（SEC）披露的信息，Acadian Asset Management LLC 在 2023 年第一季度將其在 Dr. Reddy's Laboratories Ltd（紐約證券交易所代碼：RDY - 免費報告）的股份增加了 1.6%。該基金在本季度額外收購了 23,582 股後，持有該公司 1,471,523 股股票。截至其最近的 SEC 文件，Acadian Asset Management LLC 持有的 Dr. Reddy's Laboratories 的股份約佔 0.18%，價值 1,940 萬美元。</p>
</div><ul>
<li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharmaceuticals 股票：發掘這款仿製藥的價值</li>
</ul>
</div><p>Several other large investors also recently added to or reduced their stakes in RDY. Bank of America Corp DE increased its stake in Dr. Reddy's Laboratories by 123.1% during the fourth quarter. Bank of America Corp DE now owns 1,916,425 shares of the company's stock worth $30,260,000 after acquiring an additional 1,057,584 shares during the last quarter. Cetera Investment Advisers increased its stake in Dr. Reddy's Laboratories by 410.5% during the fourth quarter. Cetera Investment Advisers now owns 20,720 shares of the company's stock worth $327,000 after acquiring an additional 16,661 shares during the last quarter. D. E. Shaw &amp; Co. Inc. increased its stake in Dr. Reddy's Laboratories by 256.3% during the fourth quarter. D. E. Shaw &amp; Co. Inc. now owns 429,887 shares of the company's stock worth $6,788,000 after acquiring an additional 309,239 shares during the last quarter. Deutsche Bank AG increased its stake in Dr. Reddy's Laboratories by 311.9% during the fourth quarter. Deutsche Bank AG now owns 171,602 shares of the company's stock worth $2,710,000 after acquiring an additional 129,936 shares during the last quarter. Finally, Ethic Inc. grew its stake in shares of Dr. Reddy's Laboratories by 422.2% during the fourth quarter. Ethic Inc. now owns 23,073 shares of the company's stock valued at $364,000 after buying an additional 18,655 shares during the last quarter. 3.85% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也增加或減少了在 RDY 的持股。美國銀行（Bank of America Corp DE）在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 123.1%。美國銀行目前持有該公司 1,916,425 股股票，價值 3,026 萬美元，此前在上個季度額外收購了 1,057,584 股。Cetera Investment Advisers 在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 410.5%。Cetera Investment Advisers 目前持有該公司 20,720 股股票，價值 32.7 萬美元，此前在上個季度額外收購了 16,661 股。D. E. Shaw &amp; Co. Inc.在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 256.3%。D. E. Shaw &amp; Co. Inc.目前持有該公司 429,887 股股票，價值 678.8 萬美元，此前在上個季度額外收購了 309,239 股。德意志銀行（Deutsche Bank AG）在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 311.9%。德意志銀行目前持有該公司 171,602 股股票，價值 271 萬美元，此前在上個季度額外收購了 129,936 股。最後，Ethic Inc.在第四季度將其在 Dr. Reddy's Laboratories 的股份增加了 422.2%。Ethic Inc.目前持有該公司 23,073 股股票，價值 36.4 萬美元，此前在上個季度額外收購了 18,655 股。機構投資者持有該股票的 3.85%。</p>
</div><h2>Dr. Reddy's Laboratories Stock Up 1.0%</h2>
<div class="lb-trans"><h2>Dr. Reddy's Laboratories 股票上漲 1.0%</h2>
</div><p>Shares of NYSE RDY opened at $14.72 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.36 and a current ratio of 1.89. The firm has a market capitalization of $12.29 billion, a price-to-earnings ratio of 22.30, a PEG ratio of 5.89 and a beta of 0.32. The stock has a 50 day moving average price of $14.34 and a 200 day moving average price of $14.09. Dr. Reddy's Laboratories Ltd has a 52-week low of $12.26 and a 52-week high of $16.19.</p>
<div class="lb-trans"><p>週五，NYSE RDY 的股票開盤價為 14.72 美元。該公司的債務與股本比率為 0.01，速動比率為 1.36，流動比率為 1.89。該公司的市值為 122.9 億美元，市盈率為 22.30，PEG 比率為 5.89，貝塔值為 0.32。該股票的 50 日移動平均價格為 14.34 美元，200 日移動平均價格為 14.09 美元。Dr. Reddy's Laboratories Ltd 的 52 周低點為 12.26 美元，52 周高點為 16.19 美元。</p>
</div><ul>
<li>2 overlooked stocks that crushed earnings but traded lower</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只被忽視的股票，盈利卻下跌</li>
</ul>
</div><p>Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The company had revenue of $988.82 million during the quarter, compared to analyst estimates of $88.27 billion. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. Sell-side analysts expect that Dr. Reddy's Laboratories Ltd will post 0.8 earnings per share for the current year.</p>
<div class="lb-trans"><p>Dr. Reddy's Laboratories（NYSE:RDY - 獲取免費報告）最近一次發佈財報是在 7 月 23 日，報告顯示該季度每股收益為 0.20 美元，超出分析師一致預期的 0.18 美元，超出幅度為 0.02 美元。該季度的收入為 9.8882 億美元，而分析師預期為 882.7 億美元。Dr. Reddy's Laboratories 的股本回報率為 17.25%，淨利潤率為 16.99%。賣方分析師預計 Dr. Reddy's Laboratories Ltd 在當前年度的每股收益將為 0.8 美元。</p>
</div><h2>Dr. Reddy's Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>Dr. Reddy's Laboratories 增加股息</h2>
</div><p>The business also recently announced an annual dividend, which was paid on Wednesday, August 6th. Shareholders of record on Thursday, July 10th were issued a dividend of $0.0915 per share. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.08. This represents a yield of 62.4%. The ex-dividend date was Friday, July 25th. Dr. Reddy's Laboratories's dividend payout ratio (DPR) is currently 10.61%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項年度股息，於 8 月 6 日支付。7 月 10 日的股東獲得每股 0.0915 美元的股息。這比 Dr. Reddy's Laboratories 之前的年度股息 0.08 美元有所增加，代表 62.4% 的收益率。除息日期為 7 月 25 日。Dr. Reddy's Laboratories 的股息支付比率（DPR）目前為 10.61%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>Drugmaker GSK: Becoming a Healthier Value Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥公司 GSK：成為更健康的價值股</li>
</ul>
</div><p>A number of research firms have recently commented on RDY. HSBC raised Dr. Reddy's Laboratories from a &#34;hold&#34; rating to a &#34;buy&#34; rating and upped their target price for the company from $14.44 to $16.90 in a research note on Thursday, June 5th. Hsbc Global Res raised Dr. Reddy's Laboratories from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, June 5th. Finally, Zacks Research raised Dr. Reddy's Laboratories from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $16.95.</p>
<div class="lb-trans"><p>多家研究機構最近對 RDY 發表了評論。滙豐銀行（HSBC）將 Dr. Reddy's Laboratories 的評級從 “持有” 上調至 “買入”，並在 6 月 5 日的研究報告中將其目標價從 14.44 美元上調至 16.90 美元。滙豐全球研究（Hsbc Global Res）在 6 月 5 日的研究報告中將 Dr. Reddy's Laboratories 的評級從 “持有” 上調至 “強烈買入”。最後，Zacks Research 在 8 月 15 日的研究報告中將 Dr. Reddy's Laboratories 的評級從 “強烈賣出” 上調至 “持有”。一位投資分析師給予該股票 “強烈買入” 評級，兩位給予 “買入” 評級，兩位給予 “持有” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 16.95 美元。</p>
</div><p><strong>Read Our Latest Analysis on RDY</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 RDY 的最新分析</strong></p>
</div><h2>About Dr. Reddy's Laboratories</h2>
<div class="lb-trans"><h2>關於 Dr. Reddy's Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.</p>
<div class="lb-trans"><p>Dr. Reddy's Laboratories Limited 及其子公司在全球範圍內作為一家綜合製藥公司運營。它通過全球仿製藥、製藥服務和活性成分（PSAI）及其他部門運營。該公司的全球仿製藥部門生產和銷售處方藥和非處方成品藥，這些藥物以品牌名稱或作為具有治療等效性的仿製成品劑型進行市場營銷，同時還參與生物製藥業務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Dr. Reddy's Laboratories</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Dr. Reddy's Laboratories</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>接近阻力位的高飛股票：3 只值得關注的股票</li>
<li>2 只上升的 CRM 平台股票，預計在 2025 年將大幅上漲</li>
<li>希捷科技在標準普爾 500 中領先：其 120% 漲幅背後的原因是什麼？</li>
<li>什麼是成長股及其投資方式</li>
<li>先鋒集團的 VUG ETF：您投資組合的終極成長 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJEWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=RDY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Dr. Reddy's Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Dr. Reddy's Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而藥明康德並不在名單上。</p>
</div><p>While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藥明康德目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Acadian Asset Management LLC 購買了 23,582 股 Dr Reddys Laboratories Ltd 的股票$RDY